news
Trajenta® (linagliptin) receives approval for the treatment of type 2 diabetes in Europe
25 August 2011 | By Boehringer Ingelheim
Marketing Authorisation from the European Commission for Trajenta® (linagliptin)...
List view / Grid view
Boehringer Ingelheim
news
Boehringer Ingelheim licenses ProBioGen’s novel GlymaxX® technology
10 August 2011 | By Boehringer Ingelheim
Boehringer Ingelheim and ProBioGen AG have signed a non-exclusive Licensing Agreement regarding ProBioGen’s GlymaxX® technology...
news
Positive first half-year 2011 for Boehringer Ingelheim
9 August 2011 | By Boehringer Ingelheim
The pharmaceutical company Boehringer Ingelheim has in the first half of 2011 once again grown in local currency terms compared to the previous year (+ 4 percent). Due to negative foreign exchange effects, consolidation in euros shows growth of 2.6 percent, with total net sales of EUR 6.4 billion against…
news
PRADAXA® (dabigatran etexilate) first drug in 50 years to gain approval for stroke prevention in atrial fibrillation in Europe
4 August 2011 | By Ogilvy Healthworld UK Limited
Pradaxa®1 (dabigatran etexilate) approved...
news
Viramune® (nevirapine) receives CHMP recommendation for approval
27 July 2011 | By Boehringer Ingelheim
The CHMP issued a Positive Opinion recommending the approval of Viramune® (nevirapine)...
news
Boehringer Ingelheim and Ashoka’s Changemakers launch “Making More Health” competition
6 July 2011 | By Boehringer Ingelheim
The www.changemakers.com/morehealth competition launched...
news
Linagliptin recommended for approval in the treatment of type 2 diabetes
24 June 2011 | By Boehringer Ingelheim
Boehringer Ingelheim and Eli Lilly received a positive opinion from the EMA's medicinal committee...
news
Boehringer Ingelheim extends “one stop shop” service
20 June 2011 | By Boehringer Ingelheim
To round off its full-service capabilities for clients, Boehringer Ingelheim is expanding its capacities and capabilities in fill & finish for biopharmaceuticals at their state-of-the-art facility in Biberach, Germany, with a new filling line.
news
New data confirm superior blood pressure reductions in diabetic patients treated with TWYNSTA®
17 June 2011 | By Boehringer Ingelheim
TWYNSTA® leads to prompt and very effective reductions in blood pressure...
news
Boehringer Ingelheim & Zealand Pharma enter into a licence & collaboration agreement
16 June 2011 | By Boehringer Ingelheim
For dual-acting glucagon and GLP-1 receptor agonists...
news
Twelfth milestone payment as part of its discovery alliance with Boehringer Ingelheim received
9 May 2011 | By Evotec AG
Twelfth milestone triggers payment of EUR 2 million to Evotec...
news
FDA approves linagliptin tablets for the treatment of type 2 diabetes
3 May 2011 | By OgilvyHealthPR
Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Food and Drug Administration (FDA) has approved linagliptin tablets, a prescription medication used along with diet and exercise to lower blood sugar in adults with type 2 diabetes.1 The FDA has approved linagliptin as a monotherapy…
news
Boehringer Ingelheim finalizes acquisition of AMGEN’s Fremont facility in the USA
Yesterday Boehringer Ingelheim formally acquired Amgen’s biopharmaceutical development and manufacturing facility in Fremont, California (USA)...
news
Elan and Boehringer Ingelheim announce agreement for antibody-based therapeutics
9 February 2011 | By Boehringer Ingelheim
Announcement covers global technical development and manufacturing for antibody-based therapeutics...
news
Lilly and Boehringer Ingelheim announce strategic diabetes treatments alliance
11 January 2011 | By Eli Lilly and Company
Global agreement will lead to joint development of diabetes compounds currently in mid- and late-stage development...
